🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

107 results for “Tad” Clear

  1. Miransertib

    Merck KGaA, Darmstadt, Germany

    PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

    phase 2 small molecule terminated

    1 trial

  2. Paclitaxel

    Merck KGaA, Darmstadt, Germany

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  3. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Advanced Non-Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  4. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Melanoma

    phase 2 mab completed

    1 trial

  5. Pembrolizumab (+) Berahyaluronidase alfa

    Merck KGaA, Darmstadt, Germany

    Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  6. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 mab active

    1 trial

  7. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  8. Pembrolizumab/Vibostolimab coformulation

    Merck KGaA, Darmstadt, Germany

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  9. Pemetrexed Ribosepharm 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatine Hikma 450 mg/45 ml Infusionslösung, Pemetrexed Hexal 25 mg/ml infuusiokonsentraatti, liuosta varten, Cisplatine 1 mg/ml PCH, concentraat voor oplossing voor infusie, Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, DOMVANALIMAB, Pemetrexed NeoCorp 25 mg/ml Konzentrat zur Herstellung einer Infusionslös

    Gilead Sciences Pty Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Posaconazol STADA 100 mg magensaftresistente Tabletten, S65487 Solution for infusion 100 mg, Vidaza 25 mg/ml powder for suspension for injection

    The George Institute

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  11. QuitAdvisorMD Software Algorithm

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 other active

    1 trial

  12. Raludotatug Deruxtecan (R-DXd)

    Merck KGaA, Darmstadt, Germany

    Gastrointestinal Cancer

    phase 2 mab active

    1 trial

  13. Ritlecitinib tosilate, Placebo for pf-06651600-15, 100 mg, Placebo for pf-06651600-15, 50 mg, LORATADINE, Ritlecitinib Tosilate

    Pfizer Australia Pty Ltd

    CHRONIC SPONTANEOUS URTICARIA

    phase 2 small molecule active

    1 trial

  14. Vidaza 25 mg/ml powder for suspension for injection, Azacitidin STADA 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Azacitidine Mylan 25 mg/mL powder for suspension for injection, Azacitidine Mylan 25 mg/mL powder for suspension for injection, pevonedistat hydrochloride, Venclyxto 100 mg film-coated tablets

    Takeda

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  15. alvimopan

    Merck KGaA, Darmstadt, Germany

    Constipation

    phase 2 small molecule completed

    1 trial

  16. A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-24

    Lacuna Pharma Pty Ltd

    healthy male subjects

    phase 1 other active

    1 trial

  17. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  18. A trial comparing how the body absorbs and gets rid of petadeferitrin taken as two different forms in healthy people

    Lacuna Pharma Pty Ltd

    Iron overload from thalassemia, transfusion-dependent myelodysplastic syndromea and haemolysis

    phase 1 other active

    1 trial

  19. Acetadote

    CUMBERLAND PHARMACEUTICALS INC

    Glioblastoma

    phase 1 small molecule active

    1 trial

  20. Boserolimab

    Merck KGaA, Darmstadt, Germany

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  21. Finlepsin 200 retard, 200 mg, tabletki o przedłużonym uwalnianiu, Orungal, 100 mg, kapsułki, Gemfibrozilo STADA 600 mg comprimidos recubiertos con película EFG, Neurotop retard 300, 300 mg, tabletki o przedłużonym uwalnianiu

    Minoryx Therapeutics S.L.

    Adrenoleukodystrophy

    phase 1 small molecule active

    1 trial

  22. MSC2156119J

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  23. Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, RMC-6236, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CARBOPLATIN-EBEWE, 10 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  24. Pomaglumetad methionil

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Use Disorder

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources